- behavior change platform moving into GLP-1 - : Tatari (Philip) - put Ro's GLP-1 story on national TV, 50% weekly jump in new patients Hudson Media Co (Yesenia) - drove Hims & Hers to 280% YoY revenue growth Rain (Robin) - launched Calibrate to its biggest signup month ever Media by Mother (Kathy Richter) - ran Found's "Not for Every Body" across CTV, social, and audio Roveia Health (Harsh) - rebuilt TrimRX's Meta and Google creative, cut acquisition costs Lantern (Seth) - scaled Weekend Health from launch to $25MM ARR in 15 months Drip Digital Media (Alex) - scaled Eden with 337% revenue growth and 50% CPA reduction Webtopia (Tristram) - scaled Fella Health's paid social from 5 to 40 ads/month BENlabs (Peter) - pivoted Noom's creator campaigns to education-led, 90% LTV lift Creekside Marketing (Samuel) - rebuilt Join Piper's Google Ads with missing audiences - & : Novo Nordisk - makes Wegovy and Ozempic, the drugs that started the GLP-1 wave Eli Lilly and Company - makes Zepbound, the fastest-growing GLP-1 entrant If you're running GLP-1 paid, DM me
A life-course approach to health: synergy with sustainable development goals
This multi-omics readiness supports translational research, biomarker validation, and pharmacometabolomic studies across pharmaceuticals and biotechnology
The specific eligibility criteria are determined by your licensed provider through OpenLoop Healthcare Partners, PC, based on independent clinical review
(Ozempic is sold in multi dose pen and others like wegovy, mounjaro and zepbound are single use pens) Device manufacturing for GLP-1 therapies is inherently complex, demanding stringent regulatory compliance
Q: Is there any scenario where morning injection of CJC-1295 and Ipamorelin is superior to nighttime
